HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 5 (2008), Issue 11 (November)

1. Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.
   BMC Infect Dis, 8: 136. [Abstract] [Full-text]
2. Sexual networks and the transmission of drug-resistant HIV.
   Curr Opin Infect Dis, 21(6): 644-52. [Abstract] [Full-text]
3. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
   J Mol Biol, 384(2): 377-92. [Abstract] [Full-text]
4. A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.
   Virology, 381(2): 241-50. [Abstract] [Full-text]
5. FOXP3 inhibits HIV-1 infection of CD4 T-cells via inhibition of LTR transcriptional activity.
   Virology, 381(2): 161-7. [Abstract] [Full-text]
6. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.
   Virology, 381(2): 251-60. [Abstract] [Full-text]
7. Molecular and structural characterization of HIV-1 subtype B Brazilian isolates with GWGR tetramer at the tip of the V3-loop.
   Virology, 381(2): 222-9. [Abstract] [Full-text]
8. Selective regimes and evolutionary rates of HIV-1 subtype B V3 variants in the Brazilian epidemic.
   Virology, 381(2): 184-93. [Abstract] [Full-text]
9. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection.
   Clin Infect Dis, 47(11): e86-9. [Abstract] [Full-text]
10. Pharmacophore modeling and molecular docking led to the discovery of inhibitors of human immunodeficiency virus-1 replication targeting the human cellular aspartic acid-glutamic acid-alanine-aspartic acid box polypeptide 3.
    J Med Chem, 51(21): 6635-8. [Abstract] [Full-text]
11. Rhesus macaque rhadinovirus-associated non-Hodgkin lymphoma: animal model for KSHV-associated malignancies.
    Blood, 112(10): 4227-34. [Abstract] [Full-text]
12. HIV evades RNA interference directed at TAR by an indirect compensatory mechanism.
    Cell Host Microbe, 4(5): 484-94. [Abstract] [Full-text]
13. Genome-scale RNAi screen for host factors required for HIV replication.
    Cell Host Microbe, 4(5): 495-504. [Abstract] [Full-text]
14. Human immunodeficiency virus type-1 (HIV-1) Pr55gag virus-like particles are potent activators of human monocytes.
    Virology, 382(1): 46-58. [Abstract] [Full-text]
15. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
    Virology, 382(1): 10-9. [Abstract] [Full-text]
16. Heightened T-cell proliferation without an elevation of CD4+ T cell spontaneous apoptosis in AIDS patients.
    Clin Immunol, 129(3): 499-508. [Abstract] [Full-text]
17. Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A.
    J Virol, 82(23): 11526-35. [Abstract] [Full-text]
18. Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.
    J Virol, 82(23): 11889-901. [Abstract] [Full-text]
19. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
    J Virol, 82(23): 11651-68. [Abstract] [Full-text]
20. Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100.
    J Virol, 82(23): 11695-704. [Abstract] [Full-text]
21. Estimating the impact of vaccination on acute simian-human immunodeficiency virus/simian immunodeficiency virus infections.
    J Virol, 82(23): 11589-98. [Abstract] [Full-text]
22. The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association.
    J Virol, 82(23): 11495-502. [Abstract] [Full-text]
23. Identification and characterization of PWWP domain residues critical for LEDGF/p75 chromatin binding and human immunodeficiency virus type 1 infectivity.
    J Virol, 82(23): 11555-67. [Abstract] [Full-text]
24. Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication.
    J Virol, 82(23): 11682-94. [Abstract] [Full-text]
25. The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses.
    J Virol, 82(23): 11609-18. [Abstract] [Full-text]
26. HIV-1 nucleocapsid traps reverse transcriptase on nucleic acid substrates.
    Biochemistry, 47(46): 12230-40. [Abstract] [Full-text]
27. Slide into action: dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates.
    Science, 322(5904): 1092-7. [Abstract] [Full-text]
28. Development of cell-expressed and virion-incorporated CCR5-targeted vaccine.
    Biochem Biophys Res Commun, 377(2): 617-21. [Abstract] [Full-text]
29. Early antiretroviral therapy and mortality among HIV-infected infants.
    N Engl J Med, 359(21): 2233-44. [Abstract] [Full-text]
30. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.
    Proc Natl Acad Sci U S A, 105(46): 17706-11. [Abstract] [Full-text]
31. Mutational analysis of the "turn" of helix clamp motif of HIV-1 reverse transcriptase.
    Biochem Biophys Res Commun, 377(3): 915-20. [Abstract] [Full-text]
32. Novel targets for HIV therapy.
    Antiviral Res, 80(3): 251-65. [Abstract] [Full-text]
33. A novel recombinant bacterial vaccine strain expressing dual viral antigens induces multiple immune responses to the Gag and gp120 proteins of HIV-1 in immunized mice.
    Antiviral Res, 80(3): 272-9. [Abstract] [Full-text]
34. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.
    J Exp Med, 205(12): 2763-79. [Abstract] [Full-text]
35. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.
    Clin Infect Dis, 47(12): 1593-9. [Abstract] [Full-text]
36. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells.
    J Exp Med, 205(12): 2717-25. [Abstract] [Full-text]
37. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120.
    J Virol, 82(24): 12069-81. [Abstract] [Full-text]
38. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.
    J Virol, 82(24): 12449-63. [Abstract] [Full-text]
39. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.
    J Virol, 82(24): 12094-103. [Abstract] [Full-text]
40. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research.
    J Virol, 82(24): 12585-8. [Abstract] [Full-text]
41. Inability of human immunodeficiency virus type 1 produced in murine cells to selectively incorporate primer formula.
    J Virol, 82(24): 12049-59. [Abstract] [Full-text]
42. Functional pseudotyping of human immunodeficiency virus type 1 vectors by Western equine encephalitis virus envelope glycoprotein.
    J Virol, 82(24): 12580-4. [Abstract] [Full-text]
43. Cyclophilin A-dependent restriction of human immunodeficiency virus type 1 capsid mutants for infection of nondividing cells.
    J Virol, 82(24): 12001-8. [Abstract] [Full-text]
44. Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells.
    J Virol, 82(24): 12335-45. [Abstract] [Full-text]
45. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency.
    J Virol, 82(24): 12291-303. [Abstract] [Full-text]
46. C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors.
    Bioorg Med Chem, 16(24): 10270-80. [Abstract] [Full-text]
47. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.
    J Infect Dis, 198(12): 1804-8. [Abstract] [Full-text]
48. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    J Med Virol, 81(1): 1-8. [Abstract] [Full-text]
49. Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.
    J Med Virol, 81(1): 9-15. [Abstract] [Full-text]
50. HIV-1 protease cleavage site prediction based on amino acid property.
    J Comput Chem, 30(1): 33-9. [Abstract] [Full-text]
51. The antiretroviral potency of APOBEC1 deaminase from small animal species.
    Nucleic Acids Res, 36(21): 6859-71. [Abstract] [Full-text]
52. Aptamers that recognize drug-resistant HIV-1 reverse transcriptase.
    Nucleic Acids Res, 36(21): 6739-51. [Abstract] [Full-text]
53. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.
    Virology, 382(2): 217-25. [Abstract] [Full-text]
54. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity.
    Virology, 382(2): 226-38. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.